P105 Pelvic exenteration in gynecologic cancer: complications and oncological outcome

Introduction/Background Pelvic exenteration (PE) is indicated in cases of unresponsive, recurrent pelvic cancer or for palliative intent. Despite the fact that the surgery is associated with a high rate of morbidity, it is currently the only real option that can effect a cure. Methodology Patients who underwent PE between January 2011 and April 2019 in our centre were retrospectively reviewed. Data related to surgery, complications and outcomes were recorded. Results Thirty-five patients were included. PE was performed due to recurrent gynaecological cancer, persistence of disease and after first diagnosis in 29 (82,9%), 4 (11,4%) and 2 (5,7%) patients, respectively. Total PE was performed in 23 cases (65,7%), followed by anterior PE in 7 cases (20%) and posterior PE in 5 cases (14,3%). Early grade II, III, IV and V complications occurred in 21 (60%), 9 (25,7%), 4 (11,4%) and 1 (2,9%) patients, respectively. One patient died within the first 30 postoperative days due to surgery-related complications. Medium-late grade II, III, IV and V complications occurred in 20 (57,1%), 16 (45,7%), 5 (14,3%) and 3 cases (8,6%), respectively. Three patients died after > 30-day period from surgery-related complications. The overall survival (OS) and disease-free survival (DFS) at 48 months after PE was 39.8% and 28.7% respectivel. Conclusion PE provides about a 40% 4-year survival chance in a selected group of patients. The early-complications rate and 30-day mortality were acceptable. Nevertheless, the medium-late complication grades II-V were 57, 46, 14 and 9%, respectively. We must focus on identifying those patients who could potentially benefit most from P. Disclosure Nothing to disclose.